Literature DB >> 30195948

Time to revise classification of phyllodes tumors of breast? Results of a French multicentric study.

Marie-José Adam1, Sofiane Bendifallah2, Négar Kalhorpour2, Camille Cohen-Steiner3, Laetitia Ropars4, Asma Mahmood5, Chloé Rousseau6, Jean Leveque7, Krystel Nyangoh Timoh1, Adolphe Der Some8, Lobna Ouldamer3, Guillaume Legendre4, Marcos Ballester2, Emile Daraï2, Geoffroy Canlorbe5, Vincent Lavoue9.   

Abstract

OBJECTIVE: To assess prognostic factors of recurrence of phyllodes tumors (PT) of the breast.
METHODS: We performed a retrospective, multicentric cohort study, including all patients who underwent breast surgery for grade 1 (benign), 2 (borderline) or 3 (malignant) PT between 2000 and 2016 in five tertiary University hospitals, diagnosed according to World Health Organisation classification.
RESULTS: 230 patients were included: 144 (63%), 60 (26%) and 26 (11%) with grade 1, 2 and 3 PT, respectively. Recurrence occurred in 10 (7%), 7 (12%) and 5 (19%) patients with grade 1, 2 and 3 PT, respectively. In univariate analysis, moderate to severe nuclear stromal pleomorphism (HR 8.00 [95% CI: 1.65-38.73], p < 0.009) was correlated with recurrence in all groups including grade 1 (HR 14.3 [95% CI: 1.29-160], p = 0.031). In multivariate analysis, surgical margin >5 mm, (HR 0.20 [95% CI: 0.06-0.63], p = 0.013) were significantly correlated with less recurrence in all PT grades. For grade 1 PT, there was also significantly less recurrence with surgical margin >5 mm, (HR 0.09 [95% CI: 0.01-0.85], p = 0.047) in multivariate analysis.
CONCLUSION: The surgical margin should be at least 5 mm whatever the grade of PT. Moderate to severe nuclear stromal pleomorphism identified a subgroup of grade 1 PT with a higher rate of recurrence. This suggests that the WHO classification could be revised with the introduction of nuclear stromal pleomorphism to tailor PT management.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Benign; Borderline; Malignant; Phyllodes breast tumor; Prognostic factors; Surgery

Mesh:

Year:  2018        PMID: 30195948     DOI: 10.1016/j.ejso.2018.08.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

Review 1.  Width of margins in phyllodes tumors of the breast: the controversy drags on?-a systematic review and meta-analysis.

Authors:  Arnaud Toussaint; Romain Piaget-Rossel; Coraline Stormacq; Patrice Mathevet; Karine Lepigeon; Patrick Taffé
Journal:  Breast Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.872

2.  Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?

Authors:  Anastasios Kyriazoglou; Flora Zagouri; Meletios A Dimopoulos
Journal:  ESMO Open       Date:  2019-06-25

3.  Radiotherapy with apatinib for recurrence of malignant phyllodes tumor of the breast: A case report.

Authors:  Hong Wu; Lei Li; Jing Yang; Chen Guo; Weiming Zhang; Hui Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 4.  Phyllodes Tumors: A Scoping Review of the Literature.

Authors:  Jessica Bogach; Saad Shakeel; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

5.  Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.

Authors:  Elisabetta Di Liso; Michele Bottosso; Marcello Lo Mele; Vassilena Tsvetkova; Maria Vittoria Dieci; Federica Miglietta; Cristina Falci; Giovanni Faggioni; Giulia Tasca; Carlo Alberto Giorgi; Tommaso Giarratano; Eleonora Mioranza; Silvia Michieletto; Tania Saibene; Angelo Paolo Dei Tos; PierFranco Conte; Valentina Guarneri
Journal:  ESMO Open       Date:  2020-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.